Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / ALXN - European advisory group backs Alexion Ultomiris for aHUS


ALXN - European advisory group backs Alexion Ultomiris for aHUS

  • The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending marketing authorization for Alexion Pharmaceuticals' (NASDAQ:ALXN) ULTOMIRIS (ravulizumab) for the treatment of patients with a body weight of 10 kg or above with atypical hemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received SOLIRIS (eculizumab) for at least 3 months and have evidence of response to eculizumab.
  • More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news,
  • Read more ...
Stock Information

Company Name: Alexion Pharmaceuticals Inc.
Stock Symbol: ALXN
Market: NASDAQ
Website: alexion.com

Menu

ALXN ALXN Quote ALXN Short ALXN News ALXN Articles ALXN Message Board
Get ALXN Alerts

News, Short Squeeze, Breakout and More Instantly...